The key to supply chain stability is working with your competitors. Indeed, there are about two other large-scale producers of I-125, which is used all over the planet to treat prostate cancer. We're in regular communication with our competitors to ensure that, at the end of the day, a patient has a treatment available.
With the shutdown of NRU, what we're planning on doing, or what we've been reviewing, is increasing our power and increasing our operating time. That'll allow us to not only produce more isotopes, but it'll also help us sustain a number of the researchers and industries that currently use NRU.
That's a medium-term solution, and a viable solution to keep Canada through a neutron gap until we have another large neutron source. We will look at how we can refurbish our facility to be that large neutron source, but it'll be a wider discussion with a number of parties involved.